Aibotics, Inc. (AIBT) Stock Price & Analysis

Aibotics, Inc. (AIBT) rose 0.00% to USD 0 as of June 10, 2026 at 11:02 UTC, according to Nexqual real-time market data.

AIBT last closed at USD 0; the session ranged USD 0–0 on volume of 690,860 shares. Market capitalization is $510,925, with a 52-week range of USD 0–0.02 (PNK). Source: Nexqual, June 10, 2026 at 11:02 UTC.

Key Statistics (as of June 10, 2026 at 11:02 UTC)

Technical Analysis (AIBT)

Nexqual's technical model rates AIBT "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 11:02 UTC.

Analyst Ratings (AIBT)

Wall Street analysts rate AIBT "None", per Nexqual as of June 10, 2026 at 11:02 UTC.

Earnings (AIBT)

Source: Nexqual, June 10, 2026 at 11:02 UTC.

Financials & Fundamentals (AIBT)

Source: Nexqual, June 10, 2026 at 11:02 UTC.

Financial Health Score (AIBT)

Nexqual rates Aibotics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 11:02 UTC.

Ownership (AIBT)

Source: Nexqual, June 10, 2026 at 11:02 UTC.

Leadership (AIBT)

Aibotics, Inc. is led by Benjamin Kaplan (age 57), Chairman, Chief Executive and Financial Officer & President, per Nexqual as of June 10, 2026 at 11:02 UTC.

From Aibotics, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)

Key Strengths & Strategy (as disclosed to the SEC)

• Information about clinical trials, including results for clinical trials other than Phase I investigations, must be submitted within specific timeframes for publication on www.ClinicalTrials.gov, a clinical trials database maintained by the National Institutes of Health.   A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND.

Partnerships

• Our board of directors consists of Ben Kaplan and Mark Croskey.   Prior to its acquisition, Aibotics Therapies (Florida) entered into a supply agreement with Havn Life Sciences Inc. a Canadian corporation, a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products.
• The Petrie-Flom Center project the US market for psychedelics could reach $6.85 billion in 2027.   It was the Company's intent to promote the current studies into psychedelics while developing a pipeline of pharmaceutical grade components for psychedelic based treatments.   On August 13, 2020, the Company entered into a supply agreement with HAVN Life Sciences to supply psilocybin for study.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:02 UTC. This page is informational and not investment advice.